JP2020040989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020040989A5 JP2020040989A5 JP2019220363A JP2019220363A JP2020040989A5 JP 2020040989 A5 JP2020040989 A5 JP 2020040989A5 JP 2019220363 A JP2019220363 A JP 2019220363A JP 2019220363 A JP2019220363 A JP 2019220363A JP 2020040989 A5 JP2020040989 A5 JP 2020040989A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- enantiomer
- diastereomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 7
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 CF 3 Inorganic materials 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 230000036210 malignancy Effects 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 4
- 229920002554 vinyl polymer Polymers 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- DFLMYGVQULGUFP-OAHLLOKOSA-N 1-[(3R)-3-[4-amino-3-[2-fluoro-4-(2-fluorobenzoyl)phenyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)C(C1=C(C=CC=C1)F)=O)F)[C@H]1CN(CC1)C(C=C)=O DFLMYGVQULGUFP-OAHLLOKOSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- QKBXFLHSJNQHKV-LLVKDONJSA-N FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)[C@H]1CN(CC1)S(=O)(=O)C=C Chemical compound FC1=C(C=CC(=C1)OC1=C(C(=CC(=C1F)F)F)F)C1=NN(C2=NC=NC(=C21)N)[C@H]1CN(CC1)S(=O)(=O)C=C QKBXFLHSJNQHKV-LLVKDONJSA-N 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- ZJDIFXCDJKKPIO-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=C(C(=CC(=C1F)F)F)F)F)C1CN(CC1)C(C=C)=O ZJDIFXCDJKKPIO-UHFFFAOYSA-N 0.000 claims 1
- QLRDEQPODCORHJ-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)C1CN(CC1)C(C=C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C1=C(C=C(C=C1)OC1=CC(=CC=C1)F)F)C1CN(CC1)C(C=C)=O QLRDEQPODCORHJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410175783.7A CN105017256A (zh) | 2014-04-29 | 2014-04-29 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN201410175783.7 | 2014-04-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565402A Division JP6670756B2 (ja) | 2014-04-29 | 2015-04-27 | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020040989A JP2020040989A (ja) | 2020-03-19 |
| JP2020040989A5 true JP2020040989A5 (https=) | 2020-07-09 |
| JP7005582B2 JP7005582B2 (ja) | 2022-01-21 |
Family
ID=54358137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565402A Active JP6670756B2 (ja) | 2014-04-29 | 2015-04-27 | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 |
| JP2019220363A Active JP7005582B2 (ja) | 2014-04-29 | 2019-12-05 | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565402A Active JP6670756B2 (ja) | 2014-04-29 | 2015-04-27 | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9532990B2 (https=) |
| EP (1) | EP3138842B1 (https=) |
| JP (2) | JP6670756B2 (https=) |
| KR (2) | KR102669966B1 (https=) |
| CN (3) | CN105017256A (https=) |
| AU (1) | AU2015252654C1 (https=) |
| BR (1) | BR112016025132A2 (https=) |
| CA (1) | CA2947338C (https=) |
| EA (2) | EA037227B1 (https=) |
| ES (1) | ES2857251T3 (https=) |
| IL (1) | IL248546B (https=) |
| MX (2) | MX2021013118A (https=) |
| WO (1) | WO2015165279A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| AU2014291161B2 (en) | 2013-07-18 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of FGFR inhibitor |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| EP3221320A4 (en) * | 2014-11-19 | 2018-04-25 | Sun Pharmaceutical Industries Ltd | A process for the preparation of ibrutinib |
| JP6681922B2 (ja) * | 2015-02-12 | 2020-04-15 | 上▲海▼度▲徳▼医▲藥▼科技有限公司 | イブルチニブの製造方法 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN106146511A (zh) * | 2015-04-03 | 2016-11-23 | 安润医药科技（苏州）有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
| CN106146512B (zh) * | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
| WO2016168704A1 (en) | 2015-04-16 | 2016-10-20 | Icahn School Of Medicine At Mount Sinai | Ksr antagonists |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| CN108884068B (zh) * | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| CN106146518A (zh) * | 2016-06-30 | 2016-11-23 | 苏州爱玛特生物科技有限公司 | 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| WO2018090792A1 (zh) * | 2016-11-15 | 2018-05-24 | 杭州和正医药有限公司 | 一种选择性布鲁顿酪氨酸激酶抑制剂及其应用 |
| CA3045339A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| CN106831788B (zh) * | 2017-01-22 | 2020-10-30 | 鲁南制药集团股份有限公司 | 伊布替尼精制方法 |
| WO2018175512A1 (en) | 2017-03-22 | 2018-09-27 | Suzhou Baijibugong Pharmaceutical Technology Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| CN107501270B (zh) * | 2017-09-01 | 2019-06-28 | 宏腾建设集团有限公司 | 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用 |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CN109970740A (zh) * | 2017-12-27 | 2019-07-05 | 广东众生药业股份有限公司 | 4-氨基-嘧啶并氮杂环衍生物及其制备方法和用途 |
| JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| CN110964016B (zh) | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
| US20210388002A1 (en) * | 2018-11-09 | 2021-12-16 | Taiho Pharmaceutical Co., Ltd. | Dimethoxybenzene compound analogs, methods for analyzing said compounds and standard products of said compounds |
| CN111171035B (zh) * | 2018-11-13 | 2021-03-30 | 山东大学 | 4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用 |
| CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药（上海）有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| CN113574051A (zh) | 2019-03-15 | 2021-10-29 | 拜耳公司 | 特定取代的3-苯基-5-螺环戊基-3-吡咯啉-2-酮及其作为除草剂的用途 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN112142745B (zh) * | 2019-06-27 | 2023-03-21 | 杭州和正医药有限公司 | 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用 |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| FI4036095T3 (fi) * | 2019-09-26 | 2024-02-14 | Jumbo Drug Bank Co Ltd | 4-Fluori-1H-pyratsolo[3,4-c]pyridiinijohdannaisia selektiivisinä Brutonin tyrosiinikinaasin (BTK) inhibiittoreina B-solulymfooman ja autoimmuunitautien hoitamiseksi |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP3865535A1 (en) | 2020-02-11 | 2021-08-18 | Bosti Trading Ltd. | New method of synthesis of chitosan derivatives and uses thereof |
| TW202144465A (zh) | 2020-02-11 | 2021-12-01 | 瑞士商諾和席卓股份有限公司 | 合成聚葡萄胺糖衍生物之新方法及其用途 |
| AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| EP4161933A1 (en) | 2020-06-08 | 2023-04-12 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
| WO2022081512A1 (en) * | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| CN112574046A (zh) * | 2020-12-17 | 2021-03-30 | 深圳市华先医药科技有限公司 | 一种制备(1r,3s)-3-氨基环戊醇盐酸盐的方法 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240139326A1 (en) * | 2020-12-23 | 2024-05-02 | Yeda Research And Development Co. Ltd. | Methacrylamides protein binders and uses thereof |
| EP4501327A3 (en) * | 2021-02-03 | 2025-10-15 | Accutar Biotechnology Inc. | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton s tyrosinekinase (btk) degraders |
| EP4376612A2 (en) | 2021-08-06 | 2024-06-05 | Novochizol SA | Preparation of composite gels, polymer scaffolds, aggregates and films comprising soluble cross-linked chitosan & uses thereof |
| AR126678A1 (es) | 2021-08-06 | 2023-11-01 | Novochizol Sa | Composiciones para el cuidado de las plantas y usos de las mismas |
| CN114605418B (zh) * | 2022-03-15 | 2023-09-05 | 广东医科大学附属医院 | 一类具有抗肿瘤活性的依鲁替尼丙烯酰胺类衍生物及其合成方法与应用 |
| CN117430610A (zh) * | 2023-10-11 | 2024-01-23 | 宁夏医科大学 | 一种氘代稠合杂环化合物及其制备方法和应用 |
| CN117903141B (zh) * | 2023-12-19 | 2024-11-05 | 江苏长泰药业股份有限公司 | 一种化合物及其盐、在制备治疗癌症药物和激酶抑制剂中的用途、治疗癌症的药物 |
| WO2025202889A1 (en) * | 2024-03-28 | 2025-10-02 | Array Biopharma Inc. | Her2 mutation inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| DK2526933T3 (en) * | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| EP1921149A1 (en) | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CA2730930C (en) * | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CN102115476A (zh) * | 2011-03-23 | 2011-07-06 | 常州大学 | 一种2H-吡唑并[3,4-d]嘧啶衍生物及合成方法 |
| WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| PL2710005T3 (pl) * | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| JP2014520863A (ja) * | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| WO2013191965A1 (en) * | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| JP6261580B2 (ja) * | 2012-07-30 | 2018-01-17 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化イブルチニブ |
| CA2880505A1 (en) * | 2012-07-31 | 2014-02-06 | Safe Wire Holding, Llc | Depth controlled jamshidi needle |
| WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| US9479134B2 (en) * | 2013-03-04 | 2016-10-25 | Texas Instruments Incorporated | Position detecting system |
| WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
| CU24400B1 (es) | 2013-04-08 | 2019-04-04 | Bayer Pharma AG | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas |
| EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2014187319A1 (en) * | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
-
2014
- 2014-04-29 CN CN201410175783.7A patent/CN105017256A/zh active Pending
-
2015
- 2015-04-27 EA EA201892740A patent/EA037227B1/ru unknown
- 2015-04-27 KR KR1020237032203A patent/KR102669966B1/ko active Active
- 2015-04-27 ES ES15785217T patent/ES2857251T3/es active Active
- 2015-04-27 EA EA201692176A patent/EA032100B1/ru unknown
- 2015-04-27 MX MX2021013118A patent/MX2021013118A/es unknown
- 2015-04-27 EP EP15785217.9A patent/EP3138842B1/en active Active
- 2015-04-27 BR BR112016025132A patent/BR112016025132A2/pt not_active Application Discontinuation
- 2015-04-27 WO PCT/CN2015/000290 patent/WO2015165279A1/zh not_active Ceased
- 2015-04-27 AU AU2015252654A patent/AU2015252654C1/en active Active
- 2015-04-27 JP JP2016565402A patent/JP6670756B2/ja active Active
- 2015-04-27 CN CN201810371229.4A patent/CN108295073B/zh active Active
- 2015-04-27 CN CN201580010345.8A patent/CN106061976B/zh active Active
- 2015-04-27 MX MX2016014248A patent/MX387487B/es unknown
- 2015-04-27 CA CA2947338A patent/CA2947338C/en active Active
- 2015-04-27 KR KR1020167028059A patent/KR20160144378A/ko not_active Ceased
-
2016
- 2016-03-18 US US15/075,033 patent/US9532990B2/en active Active
- 2016-10-27 IL IL248546A patent/IL248546B/en active IP Right Grant
- 2016-11-18 US US15/356,014 patent/US9861636B2/en active Active
-
2017
- 2017-11-22 US US15/820,614 patent/US10300066B2/en active Active
-
2019
- 2019-12-05 JP JP2019220363A patent/JP7005582B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020040989A5 (https=) | ||
| JP2017518276A5 (https=) | ||
| CN110511209B (zh) | 可用作激酶抑制剂的吲哚甲酰胺化合物 | |
| HRP20240293T1 (hr) | Derivati kinazolina kao protutumorska sredstva | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| RU2481336C2 (ru) | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт | |
| JP2012501312A5 (https=) | ||
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2009519979A5 (https=) | ||
| BR112021008986A2 (pt) | composto, composto da fórmula, composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratar o câncer, para regular a atividade de uma proteína mutante g12c k-ras, para inibir a proliferação de uma população de células, para tratar um distúrbio mediado, para preparar uma proteína e para inibir metástase de tumor e uso | |
| JP2012520867A5 (https=) | ||
| NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| RU2013124824A (ru) | Твердые дисперсии, содержащие средства, вызывающие апоптоз | |
| JP2008519790A5 (https=) | ||
| JP2016517878A5 (https=) | ||
| WO2012030912A1 (en) | 7-cyclylquinazoline derivatives and methods of use thereof | |
| ME01999B (me) | Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b | |
| JP2008528467A5 (https=) | ||
| JP2009542721A5 (https=) | ||
| JP2010510319A5 (https=) | ||
| JP2016538257A (ja) | Ｋｉｔに関連する疾患を治療するために有用な組成物 | |
| JP2009536620A5 (https=) | ||
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| JP2008528468A5 (https=) |